Theravance Biopharma
TBPH
83 hedge funds and large institutions have $226M invested in Theravance Biopharma in 2015 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 28 increasing their positions, 29 reducing their positions, and 14 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 29
9% less funds holding
Funds holding: 91 → 83 (-8)
24% less capital invested
Capital invested by funds: $297M → $226M (-$71M)
50% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 14
100% less call options, than puts
Call options by funds: $4K | Put options by funds: $989K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$4.59M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$1.62M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.27M |
| 4 |
Millennium Management
New York
|
+$992K |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$951K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$12.7M |
| 2 |
Capital World Investors
Los Angeles,
California
|
-$4.84M |
| 3 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
-$4.68M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
-$3.63M |
| 5 |
Renaissance Technologies
New York
|
-$3.44M |
TBPH Hedge Fund Activity: Q3 2015 in Review
83 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q3 2015, worth a combined $226M — down 24% from $297M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of TBPH and 7 opened new positions — a net loss of 7 holders — while 29 trimmed existing stakes and 28 added.
The largest buyer was Woodford Investment Management, opening a new position worth an estimated $4.59M. The largest seller was Armistice Capital, exiting entirely with an estimated $12.7M sold.
- 83 institutional investors held Theravance Biopharma (TBPH) as of Q3 2015, down from 91 in Q2 2015.
- Funds reported $226M of Theravance Biopharma stock for Q3 2015, down 24% quarter-over-quarter.
- 7 funds opened new Theravance Biopharma positions in Q3 2015 and 14 closed out, a net change of -7 holders.
- The largest Theravance Biopharma buyer in Q3 2015 was Woodford Investment Management, an estimated $4.59M added.
- The largest Theravance Biopharma seller in Q3 2015 was Armistice Capital, an estimated $12.7M sold.
Based on aggregated 13F filings for Q3 2015.